Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARP-1536
- Development stage
- Discontinued
- Lead developer
- Whitehawk Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
ARP-1536 is a humanized monoclonal antibody developed as an intravitreal injection for the treatment of exudative retinal diseases such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). It targets the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), acting as a receptor-like protein tyrosine phosphatase inhibitor and TIE2 receptor agonist, while also inhibiting vascular endothelial growth factors. By modulating both the Angiopoietin/Tie2 pathway and VEGF signaling, it aims to stabilize blood vessels in retinal diseases. The drug was originally developed by Aerpio Pharmaceuticals and later by Whitehawk Therapeutics (formerly Aadi Bioscience). As of April 2025, no active clinical development or reported clinical trials are ongoing for this agent[1][2][3][4].
- Other names
- ARP 1536 anti VEGF bispecific antibodyARP1536 anti VEGF bispecific antibodyARP-1536 anti VEGF bispecific antibody
02
Targets
PTPRB (Vascular endothelial-protein tyrosine phosphatase)
Beyond the preview
Go deeper on ARP-1536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARP-1536.